Market Overview:
Development
of novel technologies for epilepsy treatment and favorable reimbursement
policies proposed by governments in alliance with health coverage companies can
persuade patients for the treatment. Research for the management and treatment
of muscle function and organ disorders is likely to widen the scope of VNS
manufacturers in the market.
Paucity
of skilled surgeons and high costs of neurostimulation devices can pose a challenge
to the market growth. Side-effects of cardiac arrest and probability of
triggering a stroke can lead to hesitancy among doctors for prescribing the
treatment.
The
global Vagus
Nerve Stimulation Market Analysis is expected to balloon at 8.68%
CAGR during the forecast period (2017-2023). Rise in number of
neurological disorders such as epilepsy, depression, migraine, and others is
one of the biggest drivers of the market. According to the World Health
Organization (WHO), neurological disorders accounted for 4.5-11% of all
diseases in low-income and mid-income economies. High need for better treatment
techniques and influx of capital into research and development by
pharmaceutical and biotechnology firms can create opportunity of growth for the
market.
As
one of the major market factors, non-invasive techniques can take the market
ahead in the coming years. Other than this, biotechnology and pharmaceutical
companies are investing in the market substantially to promote growth and
develop new products. Increased application of the sector in curing various
diseases and rising supports in reimbursing the cost is bound to take the market
forward.
Competition Outlook:
·
LivaNova PLC
·
ElectroCore Medical LLC
·
EnteroMedics Inc
·
NeuroMetrix, Inc
·
Boston Scientific Corporation
·
Inspire Medical Systems
·
Cyberonics
·
ImThera Medical
Segmentation:
·
The global vagal nerve stimulation market
is segmented by product, application, and end-user.
·
By product, it is segmented into external
VNS devices and implantable VNS devices.
·
By application, it is segmented into
migraine, epilepsy, depression, and others.
·
By end-user, it is segmented into ambulatory
surgical centers, hospitals, and others.
Regional Analysis:
Asia
Pacific (APAC), the Americas, Europe, and the Middle East & Africa (MEA)
are major regions discussed in the global vagal nerve stimulation market.
The
Americas accounted for 43% market share in 2016. Rising government support for
research and development into neurological disorders, high healthcare spending,
and sophisticated healthcare infrastructure and framework for major
manufacturers to enter the region can bode well for the market growth. Presence
of large players as well as their increased capacity to invest in sufficient
amount of capital can encourage the market proliferation during the forecast
period.
Europe
holds the second position in the market standings due to availability of sufficient
funds for research and development and rise in government support. On the other
hand, the APAC region has latent potential for growth due to economies of
China, South Korea, Japan, and India. The increased healthcare budget of
economies, large patient pool, and development of neurostimulation technology
are factors which can boost the regional market growth.
NOTE : Our team of researchers are studying Covid19 and its
impact on various industry verticals and wherever required we will be
considering covid19 footprints for a better analysis of markets and industries.
Cordially get in touch for more details.
Comments
Post a Comment